Unlock AI-driven, actionable R&D insights for your next breakthrough.

Acetyl Hexapeptide-8 Amino Acid Sequence: Structural Characterization, Synthesis Routes, And Anti-Wrinkle Applications In Cosmetic Formulations

NOV 17, 202653 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Acetyl Hexapeptide-8, also known as Argireline (CAS: 616204-22-9), is a synthetic hexapeptide with the amino acid sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂ and a molecular weight of 888.91 Da. This biomimetic peptide, derived from the N-terminal fragment of SNAP-25 (synaptosome-associated protein), functions as a neurotransmitter inhibitor by competitively binding to the SNARE complex, thereby attenuating acetylcholine release and reducing muscle contraction intensity. Its mechanism enables significant reduction of dynamic facial wrinkles—clinical studies report up to 37.8% decrease in expression lines and 32% enhancement in collagen synthesis—making it a cornerstone active ingredient in anti-aging cosmetic formulations 28.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Composition And Structural Characteristics Of Acetyl Hexapeptide-8

The amino acid sequence of Acetyl Hexapeptide-8 is precisely defined as Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂, where "Ac" denotes an N-terminal acetyl group (CH₃CO-) and "NH₂" represents a C-terminal amide group 1210. This hexapeptide comprises six amino acid residues in the following order from N- to C-terminus: two glutamic acid (Glu) residues, one methionine (Met), one glutamine (Gln), and two arginine (Arg) residues. The molecular formula is C₃₄H₆₀N₁₄O₁₂S with a molecular weight of 888.91 Da 810. The N-terminal acetylation and C-terminal amidation are critical post-translational modifications that enhance metabolic stability, reduce immunogenicity, and improve membrane permeability compared to unmodified peptide analogs 12.

Structural Modifications And Their Functional Implications

The acetyl group at the N-terminus mimics naturally occurring protein modifications and shields the peptide from aminopeptidase degradation, thereby extending its half-life in biological matrices 24. The C-terminal amidation prevents carboxypeptidase cleavage and contributes to receptor binding affinity by neutralizing the terminal charge 1. The presence of methionine at position 3 introduces a thioether functional group (-S-CH₃), which may undergo oxidation under certain storage conditions; this has driven research into novel crystalline polymorphs (e.g., Crystal Forms C, D, E) that exhibit superior stability in oil-soluble formulations 78. The two arginine residues at positions 5 and 6 confer positive charge at physiological pH (pI ~10.5), facilitating electrostatic interactions with negatively charged phospholipid membranes and enhancing transdermal penetration 3.

Comparison With Structural Analogs

While the canonical sequence is Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂, patent literature discloses composite formulations incorporating cyclic permutations of Acetyl Hexapeptide-1 (e.g., Ac-His-Ala-Leu-Arg-Phe-Trp-NH₂ and its variants) to achieve synergistic anti-wrinkle effects 3. However, these analogs differ fundamentally in amino acid composition and mechanism of action. Another related peptide, Ac-Gly-Met-Cys-Cys-Ser-Arg-NH₂ (molecular weight 696.86 Da), has been reported for anti-photoaging applications but lacks the dual glutamic acid motif critical for SNAP-25 mimicry 1. The specificity of the Glu-Glu-Met-Gln-Arg-Arg sequence for SNARE complex inhibition underscores the importance of precise amino acid order in peptide bioactivity 24.

Biosynthesis And Chemical Synthesis Routes For Acetyl Hexapeptide-8

Solid-Phase Peptide Synthesis (SPPS)

The predominant industrial method for Acetyl Hexapeptide-8 production is Fmoc-based solid-phase peptide synthesis (SPPS), which assembles the peptide chain sequentially on a resin-bound C-terminal anchor 110. The process begins with Fmoc-Arg(Pbf)-NH₂ loaded onto Rink amide resin, followed by iterative cycles of Fmoc deprotection (20% piperidine in DMF) and coupling of protected amino acids: Fmoc-Arg(Pbf)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Met-OH, Fmoc-Glu(OtBu)-OH (×2) 10. After chain assembly, N-terminal acetylation is achieved using acetic anhydride in pyridine 1. Cleavage from the resin and global deprotection are performed with TFA/H₂O/TIS (95:2.5:2.5 v/v/v) for 2–3 hours at room temperature, yielding crude peptide with typical purity of 60–75% 10.

Liquid-Phase Peptide Synthesis (LPPS)

An alternative cost-effective approach is liquid-phase peptide synthesis (LPPS), which constructs the peptide via sequential coupling of protected dipeptide fragments: Ac-Glu(OtBu)-Glu(OtBu)-OH, H-Met-Gln(Trt)-OH, and H-Arg(Pbf)-Arg(Pbf)-NH₂ 10. The tetrapeptide Ac-Glu(OtBu)-Glu(OtBu)-Met-Gln(Trt)-OH is first synthesized by coupling the first two fragments using HATU/DIPEA in DMF, followed by convergent coupling with the C-terminal dipeptide to form the hexapeptide 10. This method reduces organic solvent consumption by ~40% compared to SPPS and enables scalable production (>100 g batches), though it requires careful optimization of protecting group strategies to prevent side reactions such as Met oxidation or Gln deamidation 10.

Enzymatic Biosynthesis

Recent innovations leverage ATP-dependent peptide ligases for green synthesis of Acetyl Hexapeptide-8 46. The engineered enzyme variant HexPLigase (SEQ ID NO:1) catalyzes the formation of the peptide backbone from Ac-Glu-Glu-Met and Gln-Arg-Arg in aqueous media at pH 7.5–8.0, 30–37°C 6. N-terminal acetylation is performed in situ by N-acetyltransferase variant NkAcetylTrans (SEQ ID NO:2) using acetyl-CoA as the acetyl donor, while C-terminal amidation is achieved by amidase variant CpAmid (SEQ ID NO:5) 6. This one-pot enzymatic cascade achieves >85% conversion within 6–8 hours and produces peptide with >99.5% purity after single-step chromatographic purification, eliminating toxic organic solvents and reducing production costs by ~30% relative to SPPS 46.

Purification And Quality Control

Crude Acetyl Hexapeptide-8 is purified by reversed-phase high-performance liquid chromatography (RP-HPLC) on a C₁₈ column (250 mm × 10 mm, 5 μm) using a gradient of acetonitrile (0.08–0.12% TFA) in water (0.08–0.12% TFA) 1. The gradient profile is: 8–12% acetonitrile (0–0.01 min), 8–12% to 30–40% (0.01–25 min), 30–40% to 100% (25–25.1 min), hold at 100% (25.1–30 min), with UV detection at 220 nm 1. The target peak elutes at ~18–22 min with purity >98% as determined by analytical HPLC and confirmed by mass spectrometry (ESI-MS: [M+H]⁺ = 889.9 Da) 19. Pre-column derivatization with (2,8-dimethyl-imidazo[1,2-a]pyridin-3-yl)-methanol or (6-(dimethoxymethyl)furano[3,2-b]pyridin-2-yl)-methanol enhances detection sensitivity to 0.5 μg/mL, enabling accurate quantification in cosmetic formulations 9.

Crystalline Polymorphs And Formulation Stability Of Acetyl Hexapeptide-8

Novel Crystal Forms: C, D, And E

Traditional lyophilized Acetyl Hexapeptide-8 powder exhibits limited solubility in non-polar solvents such as 1,2-pentanediol, restricting its incorporation into oil-based cosmetic systems 78. To address this, three novel crystalline polymorphs—Crystal Form C, Crystal Form D, and Crystal Form E—have been developed with significantly enhanced stability and solubility profiles 7. Crystal Form C is prepared by adding isopropanol to an aqueous solution of Acetyl Hexapeptide-8 (100–200 g/L) at a volume ratio of 1:2–3 (water:isopropanol), inducing crystallization at 4–25°C over 12–24 hours 7. Differential scanning calorimetry (DSC) reveals a sharp endothermic peak at 255.1 ± 2°C for Crystal Form C, indicating high thermal stability 7. X-ray powder diffraction (XRPD) patterns show characteristic 2θ peaks at 8.2°, 12.5°, 16.8°, and 21.3° (±0.2°), distinguishing it from the amorphous lyophilized form 7.

Stability In Oil-Soluble Formulations

Oil-soluble Acetyl Hexapeptide-8 formulations prepared from Crystal Forms C, D, or E in 1,2-pentanediol achieve concentrations up to 2160 ppm, compared to <50 ppm for lyophilized powder 8. Accelerated stability testing (40°C, 75% RH, 3 months) demonstrates that Crystal Form B-based formulations retain >95% peptide content, whereas lyophilized powder formulations degrade to <70% under identical conditions 78. The improved stability is attributed to reduced hygroscopicity and minimized aggregation in the crystalline state, which prevents Met oxidation and Gln deamidation—the primary degradation pathways in aqueous or semi-aqueous media 7.

Storage And Handling Recommendations

Acetyl Hexapeptide-8 should be stored at -20°C in sealed containers under inert atmosphere (nitrogen or argon) to prevent oxidative degradation of the methionine residue 810. Aqueous stock solutions (10–50 mg/mL in deionized water or PBS, pH 6.0–7.0) are stable for up to 6 months at -20°C but should be aliquoted to avoid repeated freeze-thaw cycles, which can induce aggregation 2. For cosmetic formulations, incorporation at the final cooling stage (<40°C) is recommended to preserve peptide integrity, and antioxidants such as sodium metabisulfite (0.05–0.1% w/w) or tocopherol (0.1–0.5% w/w) should be included to scavenge reactive oxygen species 78.

Mechanism Of Action: SNARE Complex Inhibition And Neurotransmitter Modulation

Acetyl Hexapeptide-8 exerts its anti-wrinkle effect by competitively inhibiting the assembly of the SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complex, a multi-protein machinery essential for synaptic vesicle fusion and neurotransmitter release 28. The peptide mimics the N-terminal domain of SNAP-25 (residues 141–206), which normally interacts with syntaxin-1A and synaptobrevin to form a stable ternary complex 2. By occupying the SNAP-25 binding site on syntaxin-1A, Acetyl Hexapeptide-8 destabilizes the SNARE complex, reducing the probability of vesicle docking and fusion at the presynaptic membrane 28.

Quantitative Effects On Muscle Contraction

In vitro studies using mouse hemidiaphragm preparations demonstrate that Acetyl Hexapeptide-8 (10 μM) reduces electrically evoked muscle twitch tension by 42 ± 5% compared to vehicle controls, without affecting baseline resting tension 2. This selective inhibition of evoked contraction indicates that the peptide does not induce muscle paralysis but rather attenuates excessive contractile activity driven by repetitive neural stimulation—the primary cause of dynamic facial wrinkles 2. Ex vivo human skin explant models treated with 5% Acetyl Hexapeptide-8 for 28 days show a 37.8% reduction in wrinkle depth (measured by optical profilometry) and a 32% increase in Type I collagen mRNA expression (quantified by RT-qPCR), suggesting dual mechanisms involving both neuromuscular modulation and extracellular matrix remodeling 28.

Comparison With Botulinum Toxin

Unlike botulinum toxin type A, which irreversibly cleaves SNAP-25 and causes prolonged muscle paralysis (3–6 months), Acetyl Hexapeptide-8 provides reversible and dose-dependent inhibition with a duration of action limited to the peptide's residence time in the tissue (~24–48 hours) 2. This pharmacokinetic profile allows for gradual onset and offset of effects, reducing the risk of facial asymmetry or "frozen" appearance associated with botulinum toxin injections 2. However, the topical bioavailability of Acetyl Hexapeptide-8 is inherently limited by its molecular weight (888.91 Da) and hydrophilicity, necessitating advanced delivery systems such as liposomes, niosomes, or microneedle patches to achieve therapeutic concentrations in the dermal-epidermal junction 38.

Applications In Cosmetic Formulations: Anti-Aging And Skin Rejuvenation

Topical Serums And Creams

Acetyl Hexapeptide-8 is predominantly formulated in anti-wrinkle serums, eye creams, and facial moisturizers at concentrations ranging from 3% to 10% (w/w) 28. A representative formulation comprises: Acetyl Hexapeptide-8 (5%), hyaluronic acid (1%), glycerin (5%), caprylic/capric triglyceride (10%), cetearyl alcohol (3%), polysorbate 60 (2%), phenoxyethanol (0.5%), and deionized water (q.s. to 100%) 8. The peptide is dissolved in the aqueous phase at 25–30°C, then emulsified with the oil phase using high-shear mixing (5000–8000 rpm, 10 min) to form a stable O/W emulsion with droplet size <500 nm 8. Clinical trials involving 60 female subjects (aged 35–55 years) applying 5% Acetyl Hexapeptide-8 serum twice daily for 8 weeks report significant improvements: 28% reduction in crow's feet depth, 22% decrease in forehead line severity, and 18% improvement in skin firmness (measured by cutometry) 2.

Transdermal Delivery Systems

To overcome the stratum corneum barrier, composite Acetyl Hexapeptide-1 transdermal patches have been developed, incorporating cyclic permutations of the peptide (e.g., Ac-His-Ala-Leu-Arg-Phe-Trp-NH₂) in combination with penetration enhancers such as oleic acid (5%) and

OrgApplication ScenariosProduct/ProjectTechnical Outcomes
广东合鸣生物科技有限公司Anti-wrinkle cosmetic formulations requiring high-purity peptides with enhanced stability and reduced production costs for topical serums and creams.Pro.AH8 Acetyl Hexapeptide-8Biosynthesized via prokaryotic expression system with stable quality, high bioactivity, low immunogenicity, excellent solubility and safety. Cost-effective production with simple system and high yield.
珀莱雅化妆品股份有限公司Transdermal delivery systems for anti-aging applications requiring enhanced skin penetration to overcome stratum corneum barrier in facial wrinkle treatment.Composite Acetyl Hexapeptide-1 Transdermal PatchSynergistic anti-wrinkle effects achieved through cyclic permutations of Acetyl Hexapeptide-1 (Ac-His-Ala-Leu-Arg-Phe-Trp-NH₂ and variants) combined with penetration enhancers, enabling superior transdermal delivery.
INERTIA BIOTECHNOLOGY CO. LTD.Green manufacturing of cosmetic-grade peptides for anti-wrinkle formulations requiring environmentally sustainable production with high purity (>98%) and scalability.Enzymatic Acetyl Hexapeptide-8 Synthesis PlatformUtilizes engineered Bacillus subtilis protease variants for aqueous-phase synthesis, achieving high substrate conversion rates, eliminating toxic organic solvents, and reducing raw material costs by 30% compared to solid-phase synthesis.
SHENZHEN READLINE BIOTECHNOLOGY CO. LTD.Oil-based cosmetic systems such as anhydrous serums and lipophilic anti-aging products requiring enhanced peptide stability and solubility in non-polar solvents.Crystal Form B Oil-Soluble Acetyl Hexapeptide-8Novel crystalline polymorph (Crystal Form B) enables oil-soluble formulations with peptide concentration up to 2160 ppm in 1,2-pentanediol, retaining >95% content under accelerated stability testing (40°C, 75% RH, 3 months).
SHENZHEN READLINE BIOTECHNOLOGY CO. LTD.Industrial-scale green synthesis of Acetyl Hexapeptide-8 for cosmetic applications requiring high-purity peptides with minimal environmental impact and continuous production capability.ATP-Dependent Peptide Ligase Enzymatic Cascade (HexPLigase System)One-pot enzymatic synthesis using HexPLigase, N-acetyltransferase (NkAcetylTrans), and amidase (CpAmid) achieves >85% conversion in 6-8 hours with >99.5% purity, reducing production costs by ~30% versus SPPS.
Reference
  • Acetylated and amidated hexapeptide, purification method and application thereof
    PatentActiveLU502320B1
    View detail
  • Pro.AH8 Acetyl Hexapeptide-8 with the Function of Tightening and Anti-Wrinkle, Its Preparation Method and Application
    PatentActiveCN118580307B
    View detail
  • A complex acetyl hexapeptide-1 and its transdermal formulation and application
    PatentActiveCN114917139B
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png